Correction: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma [J Transl Med., 16, (2018) (142)] DOI: 10.1186/s12967-018-1507-6;First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Journal of Translational Medicine

Volumn 16, Issue 1, 2018, Pages 1-

  Liau, Linda M ^a   Ashkan, Keyoumars ^b   Tran, David D ^c   Campian, Jian L ^d   Trusheim, John E ^e   Cobbs, Charles S ^f   Heth, Jason A ^g   Salacz, Michael ^h   Taylor, Sarah ^h   D'Andre, Stacy D ⁱ   Iwamoto, Fabio M ^j   Dropcho, Edward J ^k   Moshel, Yaron A ^l   Walter, Kevin A ^m   Pillainayagam, Clement P ⁿ   Aiken, Robert ^o   Chaudhary, Rekha ^p   Goldlust, Samuel A ^q   Bota, Daniela A ^r   Duic, Paul ^s   Grewal, Jai ^s   Elinzano, Heinrich ^t   Toms, Steven A ^t   Lillehei, Kevin O ^u   Mikkelsen, Tom ^v   Walpert, Tobias ^v   Abram, Steven R ^w   Brenner, Andrew J ^x   Brem, Steven ^y   Ewend, Matthew G ^z   Khagi, Simon ^z   Portnow, Jana ^aa   Kim, Lyndon J ^ab   Loudon, William G ^ac   Thompson, Reid C ^ad   Avigan, David E ^ae   Fink, Karen L ^af   Geoffroy, Francois J ^ag   Lindhorst, Scott ^ah   Lutzky, Jose ^ai   Sloan, Andrew E ^aj   Schackert, Gabriele ^ak   Krex, Dietmar ^ak   Meisel, Hans Jorg ^al   Wu, Julian ^am   Davis, Raphael P ^an   Duma, Christopher ^ao   Etame, Arnold B ^ap   Mathieu, David ^aq   Kesari, Santosh ^ar   Piccioni, David ^ar   Westphal, Manfred ^as   Baskin, David S ^at   New, Pamela Z ^at   Lacroix, Michel ^au   May, Sven Axel ^av   Pluard, Timothy J ^aw   Tse, Victor ^ax   Green, Richard M ^ax   Villano, John L ^ay   Pearlman, Michael ^az   Petrecca, Kevin ^ba   Schulder, Michael ^bb   Taylor, Lynne P ^bc   Maida, Anthony E ^be   Prins, Robert M ^a   Cloughesy, Timothy F ^a   Mulholland, Paul ^bd   Bosch, Marnix L ^be   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF FLORIDA   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e ABBOTT NORTHWESTERN HOSPITAL   (United States)

^f SWEDISH MEDICAL CENTER   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF KANSAS CANCER CENTER   (United States)

ⁱ Sutter Institute for Medical Research   (United States)

^j Department of Medicine   (United States)

^k INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l Overlook Medical Center   (United States)

^m UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

ⁿ RUSH UNIVERSITY MEDICAL CENTER   (United States)

^o RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^p UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^q HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s WINTHROP UNIVERSITY HOSPITAL   (United States)

^t RHODE ISLAND HOSPITAL   (United States)

^u UNIVERSITY OF COLORADO HOSPITAL   (United States)

^v HENRY FORD HEALTH SYSTEM   (United States)

^w St Thomas Research Institute   (United States)

^x UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^y UNIVERSITY OF PENNSYLVANIA   (United States)

^z UNIVERSITY OF NORTH CAROLINA   (United States)

^aa CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^ab THOMAS JEFFERSON UNIVERSITY   (United States)

^ac St Joseph Hospital   (United States)

^ad VANDERBILT UNIVERSITY   (United States)

^ae BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^af BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^ag Illinois Cancer Care   (United States)

^ah MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^ai Mount Sinai Comprehensive Cancer Center   (United States)

^aj UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^ak UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^al BG KLINIKEN BERGMANNSTROST   (Germany)

^am TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^an STONY BROOK UNIVERSITY   (United States)

^ao HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^ap H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^aq CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^ar UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^as UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^at HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^au GEISINGER HEALTH SYSTEM   (United States)

^av KLINIKUM CHEMNITZ   (Germany)

^aw Division of Gynecologic Oncology   (United States)

^ax KAISER PERMANENTE   (United States)

^ay UNIVERSITY OF KENTUCKY   (United States)

^az University of Kentucky College of Medicine ^*  (United States)

^ba MCGILL UNIVERSITY   (Canada)

^bb DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^bc UNIVERSITY OF WASHINGTON   (United States)

^bd UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^be Northwest Biotherapeutics   (United States)

more..

Author keywords

Dendritic cell; Glioblastoma; Immunotherapy; Vaccine

Indexed keywords

AUTOLOGOUS TUMOR LYSATE PULSED DENDRITIC CELL VACCINE; DCVAX L; DENDRITIC CELL VACCINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PLACEBO; TEMOZOLOMIDE; UNCLASSIFIED DRUG; CANCER VACCINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BRAIN EDEMA; BREAST DISEASE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CHEMORADIOTHERAPY; CHILL; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG TOLERABILITY; EAR DISEASE; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GLIOBLASTOMA; HEART DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; INFECTION; INJECTION SITE REACTION; INJURY; INNER EAR DISEASE; INTOXICATION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEOPLASM; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEIN METHYLATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SEIZURE; SURVIVAL RATE; SURVIVAL TIME; THORAX DISEASE; TREATMENT RESPONSE; URINARY TRACT DISEASE; UROGENITAL TRACT DISEASE; VASCULAR DISEASE; BIOASSAY; BRAIN TUMOR; CLINICAL TRIAL; DENDRITIC CELL; IMMUNOLOGY; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; BRAIN NEOPLASMS; CANCER VACCINES; DENDRITIC CELLS; ENDPOINT DETERMINATION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85047787988     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-018-1552-1     Document Type: Erratum

References (30)

1. Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013. Neuro-oncology. 2016;18(suppl_5):v1-75.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-96.
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-66.
4. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535-43.
5. Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28(7):1168-74.
6. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31(26):3212-8.
7. Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1100-8.
8. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
9. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-22.
10. Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, Schulz D, Simon M, Schlegel U, Senft C, et al. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer. 2015;51(4):522-32.
11. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265-77.
12. Hickey MJ, Malone CC, Erickson KL, Jadus MR, Prins RM, Liau LM, Kruse CA. Cellular and vaccine therapeutic approaches for gliomas. J Transl Med. 2010;8:100.
13. Prins RM, Liau LM. Cellular immunity and immunotherapy of brain tumors. Front Biosci. 2004;9:3124-36.
14. Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, Becker DP, Bronstein JM. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg. 1999;90(6):1115-24.
15. Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, Miller JF, Liau LM. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol. 2006;176(1):157-64.
16. Prins RM, Odesa SK, Liau LM. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res. 2003;63(23):8487-91.
17. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11(15):5515-25.
18. Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med. 2008;359(5):539-41.
19. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF, Liau LM. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17(6):1603-15.
20. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85(9):704-10.
21. Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18:1378-85.
22. Hong S, Li H, Qian J, Yang J, Lu Y, Yi Q. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clin Exp Immunol. 2012;170(2):167-77.
23. Grossman SA, Ellsworth S, Campian J, Wild AT, Herman JM, Laheru D, Brock M, Balmanoukian A, Ye X. Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors. J Natl Compr Canc Netw. 2015;13(10):1225-31.
24. Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306-16.
25. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-40.
26. Harris SJ, Brown J, Lopez J, Yap TA. Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med. 2016;13(2):171-93.
27. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-12.
28. Bosch ML, Prins RM. Prolonged survival for patients with recurrent glioblastoma multiforme who are treated with tumour lysate-pulsed autologous dendritic cells. Eur J Cancer. 2015;51(Supplement 1):S6-7.
29. Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J, Suijkerbuijk KPM, Azevedo S, Li H, Reshef D, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017;22(6):709-18.
30. Maxwell R, Jackson CM, Lim M. Clinical trials investigating immune checkpoint blockade in glioblastoma. Curr Treat Options Oncol. 2017;18(8):51.